- Your cart is empty
- Continue Shopping
How Many Women Die from Cervical Cancer in Africa?ย [2024 Statistics, Data & Trends]
- Stats & Data
- Posted on
-
by enavec_pharmacy
- 0 comments
![How Many Women Die from Cervical Cancer in Africa? [2024 Statistics, Data & Trends]](https://enavecpharmacy.com/wp-content/uploads/2026/04/ChatGPT-Image-Apr-21-2026-04_45_42-PM.png)
Commonly Searched Topics
Reader Locations
How Many Women Die from Cervical Cancer in Africa? [2024 Statistics, Data & Trends]
By Enavec Pharmacy Data Team ยท Sources: GLOBOCAN 2022 (IARC/WHO) ยท WHO AFRO 2023 ยท PMC Meta-Analysis 2024 ยท Lancet Oncology 2022
๐ Primary Statistic ยท WHO AFRO 2023 / GLOBOCAN 2022
Africa accounts for 23% of all cervical cancer deaths globally โ approximately 80,200 women every year
~80,200Women die from cervical cancer in Africa annually
Source: WHO Regional Office for Africa (2023) ยท GLOBOCAN 2022 (348,874 global deaths ร 23% = ~80,200) ยท IARC / WHO
That is roughly one African woman dying from cervical cancer every 6.5 minutes โ day and night. Cervical cancer is the leading cause of cancer death in women across sub-Saharan Africa. 18 of the 20 countries with the world's highest cervical cancer burden are in the WHO African region. Yet virtually all of these deaths are preventable โ through a vaccine that exists, screening that works, and treatment that cures early-stage disease.
18/20
Top-burden countries worldwide are in the WHO African region ยท WHO AFRO
76,745
Deaths/year in sub-Saharan Africa alone ยท PMC 2024
32.1%
Pooled case fatality rate in SSA โ 57 studies, 2025 meta-analysis
31%
Girls in Africa received first HPV dose by age 15 in 2022 ยท WHO AFRO
๐ Quick Reference: Cervical Cancer in Africa โ Key Statistics
Download CSV โ
| Statistic | Figure | Source | Year |
|---|---|---|---|
| Annual cervical cancer deaths โ Africa (WHO region) | ~80,200 | WHO AFRO 2023 ยท GLOBOCAN 2022 (23% of 348,874) | 2022/2023 |
| Annual cervical cancer deaths โ sub-Saharan Africa | 76,745 | PMC / GLOBOCAN cited in PMC11411759 | 2024 |
| Annual new cervical cancer cases โ Africa | 117,316 | PMC 2024 (PMC11411759) citing GLOBOCAN | 2024 |
| Africa's share of global cervical cancer mortality | 23% | WHO Regional Office for Africa | 2023 |
| Global cervical cancer deaths (all countries) | 348,874 | GLOBOCAN 2022 ยท Bray et al. CA Cancer J Clin 2024 | 2022 |
| Highest regional age-std mortality rate โ Eastern Africa | 28.87 per 100,000 | PMC GLOBOCAN 2022 analysis (PMC12276544) | 2025 |
| Highest national mortality rate โ Eswatini | 64.3 per 100,000 | PMC GLOBOCAN 2022 (PMC12276544) | 2025 |
| Pooled case fatality rate โ SSA (57 studies) | 32.06% (95% CI 29.7โ34.4) | PMC meta-analysis (PMC12550229) | 2025 |
| HPV vaccination coverage โ girls by age 15, Africa | 31% | WHO AFRO ยท 2022 data reported 2023 | 2023 |
| Countries with HPV vaccine in national programme โ Africa | 26 of 47 | WHO AFRO ยท 2023 | 2023 |
| Cervical cancer screening coverage โ SSA (average) | ~4โ14% | PLoS Medicine 2023 ยท systematic review SSA 2000โ2020 | 2023 |
| HIV-positive women: increased cervical cancer risk | 6ร higher | WHO Cervical Cancer Fact Sheet ยท Dec 2025 | 2025 |
๐ฅ Download CSV: [email protected] โ subject line "CSV: Cervical Cancer Africa" ยท ๐ Journalists may cite with attribution to enavecpharmacy.com
โก Featured Snippet โ Written for Google Position 0
Africa accounts for approximately 23% of all global cervical cancer deaths โ roughly 80,200 women per year โ according to WHO AFRO (2023) and GLOBOCAN 2022 data (348,874 global deaths). Sub-Saharan Africa alone records approximately 76,745 deaths annually. Cervical cancer is the leading cause of cancer death among women in sub-Saharan Africa, and Eastern Africa has the world's highest age-standardised cervical cancer mortality rate at 28.87 per 100,000. Of the 20 countries with the world's highest cervical cancer burden, 18 are in the WHO African region. Despite this enormous toll, the disease is almost entirely preventable through HPV vaccination, screening, and early treatment.
To understand the true weight of Africa's cervical cancer crisis, consider this: globally, 94% of the 350,000 annual cervical cancer deaths occur in low- and middle-income countries โ and Africa disproportionately leads this tragedy. Africa has approximately 18% of the world's population, yet bears 23% of global cervical cancer deaths. This 5-percentage-point excess above population share represents thousands of preventable deaths every year โ deaths that would not occur if vaccination, screening, and treatment access matched what is available in high-income countries.
Cervical cancer is caused almost entirely by persistent infection with human papillomavirus (HPV) โ a sexually transmitted infection. Over 99% of cases are HPV-attributable. Two HPV strains (types 16 and 18) cause approximately 70% of all cervical cancers. Vaccines against these strains are safe, effective (up to 99% protective against HPV 16/18 infection when given before exposure), and increasingly affordable through GAVI support โ yet only 31% of African girls received even the first dose of the HPV vaccine by age 15 in 2022, according to WHO AFRO data.
~80,200
Women die from cervical cancer in Africa per year (one every 6.5 minutes)
WHO AFRO 2023 ยท GLOBOCAN 2022
23%
Africa's share of global cervical cancer deaths โ 5 points above its population share
WHO AFRO ยท GLOBOCAN 2022
#1
Cervical cancer is the leading cancer killer of women in sub-Saharan Africa โ every year
Lancet Oncology SSA Commission 2022
An important distinction: cervical cancer's burden is not uniform across Africa. Sub-Saharan Africa bears the heaviest burden, particularly East and Central Africa where the combination of high HIV prevalence (women living with HIV are 6ร more likely to develop cervical cancer), low screening coverage, and late diagnosis creates a perfect storm. North Africa โ Algeria, Egypt, Morocco, Tunisia โ has a considerably lower burden, partly due to lower HIV prevalence and somewhat better healthcare infrastructure. The WHO African region figure of ~80,200 deaths includes North Africa; the sub-Saharan Africa figure of ~76,745 represents the most concentrated zone of the crisis.
๐ Key Takeaway
Every single cervical cancer death in Africa is, in principle, preventable. Unlike most cancers, cervical cancer has a proven vaccine (HPV), reliable screening (VIA, Pap smear, HPV DNA test), and effective treatment at every stage if caught early. WHO has established the 90โ70โ90 elimination targets: vaccinate 90% of girls with HPV vaccine by age 15; screen 70% of women by ages 35 and 45; treat 90% of women with pre-cancer or invasive cancer found. Africa is falling critically short on all three. According to WHO AFRO (2023), if current off-track progress continues, approximately 70,000 African women will die needlessly from cervical cancer every year โ deaths that effective implementation of the elimination strategy would prevent.
Cervical Cancer Mortality by African Sub-Region (GLOBOCAN 2022)
| African Sub-Region | Age-Std Mortality Rate (per 100,000) | Age-Std Incidence Rate | Key Driver | Source & Year |
|---|---|---|---|---|
| Eastern Africa | 28.87 per 100,000 โ WORLD'S HIGHEST | 40.42 per 100,000 | High HIV prevalence, near-zero screening, low HPV vaccination | PMC GLOBOCAN 2022 ยท 2025 |
| Middle (Central) Africa | 22.86 per 100,000 | 31.12 per 100,000 | Extreme healthcare access limitations, high HIV, armed conflict disrupting services | PMC GLOBOCAN 2022 ยท 2025 |
| Southern Africa | 20.36 per 100,000 | 34.89 per 100,000 | World's highest HIV burden (Eswatini, SA); some screening programmes exist | PMC GLOBOCAN 2022 ยท 2025 |
| Western Africa | ~18โ22 per 100,000 | ~25โ28 per 100,000 | Lowest screening in Africa (~4โ6% coverage); Nigeria has highest absolute numbers | PLoS Medicine 2023 ยท GLOBOCAN 2022 |
| Northern Africa | ~5โ8 per 100,000 | ~7โ10 per 100,000 | Lower HIV prevalence; stronger healthcare systems; different HPV type distribution | GLOBOCAN 2022 ยท IARC |
| Global average (all countries) | 7.08 per 100,000 | 14.12 per 100,000 | Reference benchmark | GLOBOCAN 2022 ยท ScienceDirect 2025 |
Highest-Burden Countries โ National Cervical Cancer Mortality Rates (GLOBOCAN 2022)
| Country | Age-Std Mortality Rate (per 100,000) | Why So High | Source |
|---|---|---|---|
| ๐ธ๐ฟ Eswatini (Swaziland) | 64.3 per 100,000 โ WORLD'S HIGHEST | World's highest HIV prevalence (~27% adults); minimal screening history; late-stage diagnosis predominates | PMC GLOBOCAN 2022 ยท 2025 |
| ๐ฒ๐ผ Malawi | 54.1 per 100,000 โ 2nd globally | Extremely limited oncology infrastructure; Blantyre registry shows 7.9%/yr incidence growth | PMC GLOBOCAN 2022 ยท BJC 2020 |
| ๐ฟ๐ฒ Zambia | 49.4 per 100,000 โ 3rd globally | High HIV (11.1%); screening coverage improving but still low; treatment backlog | PMC GLOBOCAN 2022 ยท 2025 |
| ๐ฟ๐ผ Zimbabwe | ~45 per 100,000 | Economic collapse has decimated screening infrastructure; high HIV burden | GLOBOCAN 2022 ยท BJC 2020 |
| ๐บ๐ฌ Uganda | ~40 per 100,000 | Incidence rising 1.8%/year over 2 decades; HPV vaccination begun 2015 but coverage low | GLOBOCAN 2022 ยท PMC 2024 |
| ๐ฒ๐ฟ Mozambique | ~38 per 100,000 | One of the world's highest HPV prevalences in general population; fragile health system | GLOBOCAN 2022 ยท IARC |
| ๐ณ๐ฌ Nigeria | ~22 per 100,000 | Highest absolute number of deaths in West Africa; second largest cervical cancer burden in SSA; majority present at advanced stage | GLOBOCAN 2022 ยท Lancet Oncology SSA 2022 |
| ๐ฐ๐ช Kenya | ~25 per 100,000 | Eldoret registry: 9.5%/yr incidence increase 2002โ2016; high HIV (4.2%); screening coverage ~3.5% | BJC 2020 ยท GLOBOCAN 2022 |
Predictors of Cervical Cancer Mortality in Sub-Saharan Africa
Meta-Analysis Context: A 2025 PMC meta-analysis (PMC12550229) synthesised 57 studies from sub-Saharan Africa (2000โ2024) covering patients from South Africa (16 studies), Kenya (9), Nigeria (8), Ghana (4), Ethiopia (4), Zambia (3), Zimbabwe (3), and 10 other countries. The pooled 30-day/in-hospital mortality incidence across all studies was 32.06% (95% CI: 29.71โ34.41%). High heterogeneity (Iยฒ=95.72%) reflects the diversity of settings and quality of care across the region.
| Mortality Predictor | Hazard Ratio (95% CI) | Frequency in Studies | Source |
|---|---|---|---|
| Advanced stage at diagnosis (Stage III/IV) | HR=2.6 (95% CI: 2.1โ3.2) | Noted in 90% of included studies | PMC meta-analysis 2025 |
| Age over 65 years | HR=2.0 (95% CI: 1.5โ2.6) | 80% of studies | PMC meta-analysis 2025 |
| HIV-positive status | HR=1.52 (95% CI: 1.06โ2.19) | 70% of studies | PMC meta-analysis 2025 |
| Radiotherapy-only treatment (vs surgery or combination) | HR=1.41 (95% CI: 1.22โ1.63) | 60% of studies | PMC meta-analysis 2025 |
| Anaemia at diagnosis | HR=2.0 (95% CI: 1.5โ2.5) | Multiple studies | PMC meta-analysis 2025 |
99%
Of cervical cancers are caused by HPV โ making it the most vaccine-preventable major cancer
WHO Fact Sheet ยท Dec 2025
6ร
HIV-positive women are 6ร more likely to develop cervical cancer โ critical in SSA
WHO Fact Sheet ยท Dec 2025
21.7%
Of all cancer deaths among SSA women are from cervical cancer alone
ScienceDirect 2022 ยท GLOBOCAN
๐ Key Takeaway โ Data Breakdown
Eastern Africa bears the heaviest cervical cancer mortality burden globally โ with an age-standardised mortality rate of 28.87 per 100,000, more than four times the global average of 7.08 per 100,000. Three countries โ Eswatini, Malawi, and Zambia โ have the world's three highest national cervical cancer mortality rates. In all three, HIV co-infection, minimal screening infrastructure, and late-stage diagnosis at presentation drive this catastrophe. The meta-analysis finding that advanced stage at diagnosis doubles mortality risk (HR 2.6) is the statistical proof of what everyone in African oncology already knows: by the time most women in sub-Saharan Africa present with cervical cancer, cure is rarely possible.
Age-Standardised Cervical Cancer Mortality Rate by African Sub-Region vs Global Average (per 100,000) โ GLOBOCAN 2022
GLOBOCAN 2022 ยท PMC 2025
Source: PMC12276544 โ Global burden of cervical cancer: current estimates based on GLOBOCAN 2022 (Published 2025) ยท IARC / WHO
๐ Journalists may cite with attribution to enavecpharmacy.com
๐ Journalists may cite with attribution to enavecpharmacy.com
While high-income countries have dramatically reduced cervical cancer through organised screening programmes (since the 1960s) and more recently HPV vaccination (since 2006), Africa's trajectory has moved in the opposite direction โ rising incidence in most registries, high and persistent mortality, and a growing absolute burden as the continent's population expands.
| Period / Year | Est. Annual Deaths (SSA) | Key Development | Source |
|---|---|---|---|
| Pre-2000 | ~35,000โ45,000 | Pap smear screening available only in South Africa; no HPV vaccine; HIV epidemic beginning to amplify cervical cancer risk | GLOBOCAN historical / IARC |
| 2000โ2008 | ~50,000โ57,000 | HIV epidemic at peak in SSA before ART scale-up; 68% of women diagnosed with cervical cancer in SSA died (WHO AFRO, citing 2018 data). Screening at near-zero; limited radiotherapy access | WHO AFRO 2023 ยท GLOBOCAN 2008 |
| 2012 | ~57,381 | First comprehensive GLOBOCAN baseline for SSA: 57,381 deaths. Cervical cancer leading female cancer killer in SSA. HPV vaccine available but only in 2โ3 African countries. | PMC Prevention Review citing GLOBOCAN 2012 |
| 2015 | ~62,000 | GAVI accelerates HPV vaccination support. WHO launches 90โ70โ90 elimination initiative. Africa's incidence continues rising in most registries (BJC, 2020). | BJC 2020 ยท GLOBOCAN 2015 estimates |
| 2018 | ~68,000 | WHO AFRO data: 68% of women diagnosed with cervical cancer in SSA died. SSA: 111,632 new cases in 2018. HPV vaccines in 12 African national programmes. | WHO AFRO ยท GLOBOCAN 2018 |
| 2020 | ~71,000 | COVID-19 severely disrupts cervical cancer screening and treatment services across Africa. HPV vaccination programmes suspended in many countries during lockdowns. Backlog in diagnosis. | GLOBOCAN 2020 ยท Lancet Oncology SSA 2022 |
| 2022 | ~76,745โ80,200 | GLOBOCAN 2022: 23% of global cervical cancer mortality in Africa. WHO AFRO: 18 of top-20 burdened countries are in Africa. Only 26 countries have HPV vaccine in national programme. | WHO AFRO 2023 ยท GLOBOCAN 2022 |
| 2030 (projected โ business as usual) | >100,000 | GLOBOCAN projects 14.8% rise in global cases and 17.8% rise in deaths by 2030 if 2022 rates unchanged. Africa's population growth amplifies this โ deaths could exceed 100,000 without acceleration of elimination efforts. | PubMed GLOBOCAN projections ยท July 2025 |
Registry-Level Trend Evidence
The most rigorous trend data comes from the African Cancer Registry Network (AFCRN). A 2020 British Journal of Cancer study examined 10 population-based registries across 8 SSA countries (Gambia, Kenya, Malawi, Mauritius, Seychelles, South Africa, Uganda, Zimbabwe) for 10โ25 years, covering 21,990 cases. Key findings:
- ๐Blantyre, Malawi: The most rapid increase โ 7.9% annually. Reflects Malawi's severe lack of screening infrastructure and rising HIV burden
- ๐Eldoret, Kenya: After a decline (1998โ2002), a sharp increase of 9.5%/year from 2002 to 2016 โ among the fastest growing rates in the world
- ๐Kampala, Uganda: A significant increase of 2.2%/year until 2006, then a modest but non-significant decline โ possibly reflecting some screening uptake
- ๐Mauritius: The only SSA country showing a consistent decline โ 2.5%/year. Mauritius has a well-functioning cancer screening programme, higher HDI, and lower HIV prevalence
- โ ๏ธOverall conclusion: "Cervical cancer incidence has been increasing in sub-Saharan Africa." โ Jedy-Agba E et al., British Journal of Cancer, 2020
๐ Key Takeaway โ Trend
Africa's cervical cancer burden is growing, not shrinking. From approximately 35,000โ45,000 deaths pre-2000 to ~76,745โ80,200 deaths in 2022, annual cervical cancer deaths in Africa have roughly doubled in two decades. The primary drivers are population growth, the HIV epidemic amplifying HPV's carcinogenic progression, near-zero screening coverage in most countries, and insufficient HPV vaccination scale-up. Without dramatic acceleration of the WHO 90โ70โ90 elimination targets โ particularly HPV vaccination reaching 90% of girls and screening reaching 70% of women โ the 2030 projection of over 100,000 African women dying from cervical cancer per year will become reality.
Estimated Annual Cervical Cancer Deaths in Sub-Saharan Africa โ Trend 2000โ2022 & 2030 Projection
GLOBOCAN Series ยท WHO AFRO ยท PMC ยท Compiled by Enavec Pharmacy
Sources: GLOBOCAN 2012, 2018, 2020, 2022 (IARC/WHO) ยท WHO AFRO 2023 ยท PMC11411759 (2024) ยท BJC 2020 ยท PubMed GLOBOCAN projections July 2025
Note: Pre-2012 figures are GLOBOCAN model-derived estimates. 2030 is a business-as-usual projection based on unchanged 2022 rates + demographic growth.
๐ Journalists may cite with attribution to enavecpharmacy.com
Note: Pre-2012 figures are GLOBOCAN model-derived estimates. 2030 is a business-as-usual projection based on unchanged 2022 rates + demographic growth.
๐ Journalists may cite with attribution to enavecpharmacy.com
Comparing African countries to each other and to high-income countries exposes the full scale of the preventability gap. The difference in cervical cancer mortality between Eastern Africa and Western Europe or Australia is not biology โ it is the presence or absence of HPV vaccination, organised screening, and accessible treatment.
| Country / Region | Age-Std Mortality Rate (per 100,000) | HPV Vaccine in NIP? | Screening Coverage | 5-Yr Survival Est. | Source & Year |
|---|---|---|---|---|---|
| ๐ธ๐ฟ Eswatini | 64.3 โ World #1 | Yes (since 2015) | Very low | ~20โ25% | GLOBOCAN 2022 ยท PMC 2025 |
| ๐ฒ๐ผ Malawi | 54.1 โ World #2 | Yes (since 2013) | ~5โ8% | ~18โ22% | GLOBOCAN 2022 ยท PMC 2025 |
| ๐ฟ๐ฒ Zambia | 49.4 โ World #3 | Yes (since 2013) | ~8โ12% | ~20โ25% | GLOBOCAN 2022 ยท PMC 2025 |
| ๐บ๐ฌ Uganda | ~40 per 100,000 | Yes (since 2015) | ~10% (limited) | ~22โ28% | GLOBOCAN 2022 ยท Lancet 2022 |
| ๐ฐ๐ช Kenya | ~25 per 100,000 | Yes (since 2019) | ~3.5โ10% | ~28โ35% | GLOBOCAN 2022 ยท PMC 2023 |
| ๐ณ๐ฌ Nigeria | ~22 per 100,000 | Partial (limited) | ~4โ8% | ~25โ30% | GLOBOCAN 2022 ยท Lancet Oncology 2022 |
| ๐ฟ๐ฆ South Africa | ~20 per 100,000 | Yes (since 2014) | ~15โ25% | ~35โ45% | GLOBOCAN 2022 ยท PMC 2025 |
| ๐ Sub-Saharan Africa | ~27.6 per 100,000 (avg) | 26/48 countries | ~4โ14% (SSA avg) | ~25โ35% | PMC 2024 ยท WHO AFRO 2023 |
| ๐ Global Average | 7.08 per 100,000 | Varies | ~19% LMICs avg | ~55โ60% | GLOBOCAN 2022 ยท ScienceDirect 2025 |
| ๐ฌ๐ง United Kingdom | ~2.5 per 100,000 | Yes (since 2008) | ~73% | ~67โ72% | GLOBOCAN 2022 ยท NHS England |
| ๐บ๐ธ United States | ~2.5 per 100,000 | Yes (since 2006) | ~65โ70% | ~67โ70% | GLOBOCAN 2022 ยท CDC 2024 |
| ๐ฆ๐บ Australia-New Zealand | 1.44 per 100,000 โ World's LOWEST | Yes (since 2007) | >80% | >75% | GLOBOCAN 2022 ยท PMC 2025 |
| ๐จ๐ฆ Canada | ~2.2 per 100,000 | Yes (since 2007) | ~75โ80% | ~70% | GLOBOCAN 2022 ยท CIHI 2024 |
๐ Key Takeaway โ Country Comparison
The gap between Eswatini (64.3 per 100,000) and Australia-New Zealand (1.44 per 100,000) โ a 44-fold difference โ is the starkest healthcare inequality in the cancer world. Both countries have women, HPV, and the same cervix. What differs is a vaccine introduced in 2007 and screening reaching over 80% of eligible women. Nigeria's rate of ~22 per 100,000 is approximately 9ร higher than the UK's โ entirely attributable to the absence of organised screening and low HPV vaccination coverage. If Nigeria achieved Australia's current rate, approximately 14,000โ15,000 Nigerian women would be saved from cervical cancer death every year.
Age-Standardised Cervical Cancer Mortality Rate by Country (per 100,000 women) โ African Countries vs Global Comparators
GLOBOCAN 2022 ยท NHS ยท CDC ยท CIHI 2024
Sources: GLOBOCAN 2022 (IARC/WHO) ยท PMC12276544 (2025) ยท NHS England 2024 ยท CDC 2024 ยท CIHI Canada 2024
WHO 90โ70โ90 target dashed line represents the global elimination threshold level ยท Nigerian bar in green
๐ Journalists may cite with attribution to enavecpharmacy.com
WHO 90โ70โ90 target dashed line represents the global elimination threshold level ยท Nigerian bar in green
๐ Journalists may cite with attribution to enavecpharmacy.com
The Human Face of the Data
Cervical cancer kills women in the most productive years of their lives. The WHO notes that cervical cancer disproportionately affects younger women โ and as a result, 20% of all children who lose their mother to cancer do so due to cervical cancer. In Africa, where early marriage and childbearing are common, this means hundreds of thousands of children losing their mothers every generation to a preventable disease.
The economic cost is staggering. Each cervical cancer death in Africa represents not just a woman's life but an economic shock to her family โ loss of income, childcare, subsistence farming, and social support networks. At the national level, the productivity losses from 80,000 women dying annually โ many in their 30s and 40s โ represent a measurable drag on GDP across the continent. A 2021 analysis estimated the global economic cost of cervical cancer at over US$39 billion annually โ Africa bears a disproportionate share.
"About 70,000 cervical cancer deaths could be averted annually in the African region if the efforts to end the disease by 2030 are urgently stepped up to ensure increased access to critical services for timely detection, care and prevention."
โ WHO Regional Office for Africa ยท Official Statement ยท August 31, 2023 ยท afro.who.int
"Among the 20 countries in the world with the highest burden of cervical cancer, 18 are in the WHO African region. In 2022, the region accounted for 23% of global cervical cancer mortality. Yet this cancer is almost entirely preventable."
โ WHO Regional Office for Africa ยท Cervical Cancer Topic Page ยท 2024 ยท afro.who.int
WHO 90โ70โ90 Elimination Targets โ Africa's Progress
| WHO 90โ70โ90 Target | What It Means | Africa's Current Status | Gap |
|---|---|---|---|
| 90% HPV Vaccination | 90% of girls fully vaccinated with HPV vaccine by age 15 | Only 31% of girls received first dose in Africa (2022) | 59 percentage points below target ยท WHO AFRO 2023 |
| 70% Screening Coverage | 70% of women screened by ages 35 and 45 using HPV test | ~4โ14% screening coverage in SSA ยท estimates vary by country | 56+ percentage points below target ยท PLoS Medicine 2023 |
| 90% Treatment Access | 90% of women with pre-cancer or invasive cancer receive appropriate treatment | Only 16 countries have sub-national HPV-based screening; treatment capacity severely limited | Most countries lack radiotherapy and surgical oncology capacity ยท WHO AFRO 2023 |
SDG 3 & Global Health Commitments
Cervical cancer elimination sits directly within SDG 3.4 (reduce premature mortality from NCDs by one-third by 2030) and the WHO Global Strategy to Accelerate the Elimination of Cervical Cancer โ signed in 2020. All 47 WHO African member states have committed to this strategy. Progress has been made โ HPV vaccine programmes have launched in 26 countries โ but the pace is critically insufficient. At current trajectories, Africa will not approach the 90โ70โ90 targets by 2030. The scientific consensus (PubMed GLOBOCAN projections, July 2025) is clear: if 2022 rates remain unchanged, global cervical cancer cases will increase 14.8% and deaths 17.8% by 2030, with Africa bearing the largest absolute increase.
๐ฌ How the Primary Statistic (~80,200 deaths/year) Was Derived
| Primary Source | WHO Regional Office for Africa (WHO AFRO), August 2023 official communication: "In 2022, the [African] region accounted for 23% of global cervical cancer mortality." GLOBOCAN 2022 reports 348,874 global cervical cancer deaths (Bray et al., CA Cancer J Clin, April 2024). 348,874 ร 23% = 80,241, rounded to ~80,200. |
| Secondary Confirmation | PMC11411759 (2024): "76,745 [women] die from the disease every year" in Africa โ derived from GLOBOCAN. This slightly lower figure reflects sub-Saharan Africa only (excluding North Africa). Both are valid depending on geographic scope. ScienceDirect 2022: "just over 60,000 women die from the disease in [SSA] this region" โ based on older GLOBOCAN 2018/2020 data; outdated by 2022 GLOBOCAN. |
| Data Collection Method | GLOBOCAN 2022 uses IARC's established methodology: high-quality national registry data where available; regional interpolation and modelling using sociodemographic index, cancer registry extrapolation, and vital registration data where registries are absent. Most African countries lack comprehensive vital registration โ model uncertainty is larger than for high-income countries. |
| Uncertainty Range | Africa's cervical cancer deaths in 2022: approximately 70,000โ95,000 (95% uncertainty range). The ~80,200 figure represents the central estimate. Sub-Saharan Africa (76,745) is somewhat better constrained by the meta-analysis literature. |
| Known Limitations | (1) Most SSA countries lack population-based cancer registries โ GLOBOCAN figures are modelled estimates. (2) Verbal autopsies and hospital data are used as proxies in many countries and may misclassify cause of death. (3) Rural deaths โ a large proportion of the true burden โ are systematically undercounted. (4) The true burden is likely higher than published estimates. (5) GLOBOCAN 2022 figures may be updated when GLOBOCAN 2024 or later editions are released. |
| Last Updated | April 2025. Data from GLOBOCAN 2022 (published/updated 2024) and WHO AFRO (2023). Will be updated when WHO AFRO releases 2024 regional estimates. |
๐
Last Updated: April 2025 ยท Primary source: GLOBOCAN 2022 (IARC, 2024) ยท WHO AFRO (2023) ยท PMC11411759 (2024) ยท PMC12276544 (2025)
Approximately 80,200 women die from cervical cancer in Africa (WHO region) every year โ representing 23% of the global total of 348,874 cervical cancer deaths in 2022, according to WHO AFRO (2023) and GLOBOCAN 2022 data. Sub-Saharan Africa alone accounts for approximately 76,745 deaths per year, according to PMC research citing GLOBOCAN (PMC11411759, 2024). That equates to roughly one African woman dying from cervical cancer every 6.5 minutes, 24 hours a day. Cervical cancer is the leading cause of cancer death in women across sub-Saharan Africa and is entirely preventable through HPV vaccination, screening, and early treatment. Of the 20 countries with the world's highest cervical cancer burden, 18 are in the WHO African region. (Sources: WHO AFRO 2023 ยท GLOBOCAN 2022 ยท PMC11411759 ยท PMC12276544)
Based on GLOBOCAN 2022 data, Eswatini (Swaziland) has the world's highest national cervical cancer mortality rate at 64.3 per 100,000 women per year โ followed by Malawi (54.1) and Zambia (49.4). All three countries are in Southern/Eastern Africa and share the deadly combination of very high HIV prevalence, minimal cervical cancer screening infrastructure, near-zero historically, and late-stage presentation at diagnosis. By region, Eastern Africa has the world's highest regional cervical cancer mortality rate at 28.87 per 100,000 (compared to the global average of 7.08 per 100,000 and Australia/New Zealand's rate of 1.44 per 100,000). Within West Africa, Nigeria has the highest absolute number of deaths due to its large population, though its age-standardised rate of ~22 per 100,000 is lower than East African rates. (Sources: PMC12276544 ยท GLOBOCAN 2022 ยท WHO IARC)
Cervical cancer kills far more women in Africa than in high-income countries for five interconnected reasons: (1) Late-stage diagnosis: The 2025 PMC meta-analysis of 57 SSA studies (42,057+ patients) found advanced stage at diagnosis is the single strongest predictor of death (HR=2.6). Most African women are diagnosed at Stage III or IV when cure is rarely possible โ compared to Stage IโII in countries with screening. (2) Virtually no organised screening: Cervical cancer screening coverage in sub-Saharan Africa averages only ~4โ14% โ compared to 63โ80%+ in high-income countries. Pap smears and VIA tests can detect pre-cancerous lesions years before they become cancer. When missed, a curable pre-cancer becomes a lethal invasive cancer. (3) Low HPV vaccination: Only 31% of African girls received even the first HPV dose by age 15 in 2022, leaving the vast majority unprotected. (4) HIV amplification: Women living with HIV are 6ร more likely to develop cervical cancer. Sub-Saharan Africa has the world's highest HIV burden โ creating a catastrophic synergy. (5) Limited treatment access: Radiotherapy โ the primary treatment for advanced cervical cancer โ is scarce across SSA. Many countries have fewer than 2 machines for millions of women. Even surgery and chemotherapy are difficult to access outside of major cities. (Sources: PMC meta-analysis 2025 ยท WHO Fact Sheet 2025 ยท WHO AFRO 2023 ยท PLoS Medicine 2023)
According to WHO AFRO (2023), only 26 of 47 African countries had introduced the HPV vaccine into their national immunisation programme by 2023, and only 31% of girls received the first dose of the HPV vaccine by age 15 across the African region in 2022. A 2024 PMC analysis (PMC11411759) found that the mean wait time for African countries to incorporate HPV vaccination into national programmes was 12 years from vaccine availability โ compared to 2โ4 years in high-income countries โ and that the estimated mean coverage rate among vaccinated countries was approximately 52%. The WHO 90โ70โ90 elimination target requires 90% vaccination coverage by 2030 โ Africa is currently 59 percentage points below this target. The GAVI Alliance has been central to financing HPV vaccination in Africa, offering highly subsidised vaccines. The gap is primarily a programme delivery, health system capacity, and awareness issue rather than cost alone. Nigeria has had limited, sub-national HPV vaccination programmes but no comprehensive national rollout as of 2024. (Sources: WHO AFRO 2023 ยท PMC11411759 ยท WHO Cervical Cancer Fact Sheet 2025)
Yes โ cervical cancer is almost entirely preventable, and this is what makes Africa's toll so devastating. Prevention works through three strategies: (1) HPV Vaccination (primary prevention): The HPV vaccine (Gardasil, Cervarix) prevents infection with HPV types 16 and 18 โ which cause approximately 70% of all cervical cancers. Given before first sexual exposure, it is up to 99% effective. In Nigeria, HPV vaccination has been available in some states through GAVI-supported programmes and government initiatives, though no comprehensive national programme exists as of 2024. The vaccine is available at some private clinics and hospitals in Lagos, Abuja, Port Harcourt, and other major cities. (2) Screening (secondary prevention): VIA (visual inspection with acetic acid) is the WHO-recommended screening method for low-resource settings โ it's cheap, requires no laboratory, and can detect pre-cancerous lesions that are 100% treatable. In Nigeria, VIA screening is available at some government hospitals and through NGO programmes, but coverage remains approximately 4โ8%. (3) Treatment (tertiary prevention): Early-stage cervical cancer (Stage IโIIA) treated with surgery or radiotherapy has 5-year survival rates of 70โ90%. This emphasises why screening matters โ finding cancer early transforms it from a death sentence into a treatable disease. Ask your pharmacist, gynaecologist, or nearest tertiary hospital about HPV vaccination and cervical screening options available in your location. (Sources: WHO Fact Sheet 2025 ยท WHO AFRO ยท Lancet Oncology SSA 2022)
Early cervical cancer typically has no symptoms โ which is precisely why screening is life-saving. By the time symptoms appear, the cancer is often at an advanced stage. That said, warning signs that every woman in Africa should know include: (1) Abnormal vaginal bleeding: Bleeding between periods, after sexual intercourse (post-coital bleeding), or after menopause (post-menopausal bleeding) โ the most common symptom. (2) Unusual vaginal discharge: Watery, bloody, or foul-smelling discharge โ particularly discharge that is heavier than usual or has changed in character. (3) Pelvic pain: Pain during sexual intercourse (dyspareunia) or persistent pelvic/lower back pain not explained by other conditions. (4) Leg swelling: In advanced disease, swelling of one or both legs due to lymph node involvement โ a later sign. (5) Difficulty urinating or blood in urine: In advanced cases, the tumour can invade the bladder or rectum. Important context for Nigeria and Africa: Studies consistently show that over 70โ80% of African women who present to hospital with cervical cancer are already at Stage III or IV โ meaning the disease has spread. At this stage, cure is rare and treatment is focused on extending life and managing pain. If you have ANY of the above symptoms, do not delay โ seek medical attention immediately at your nearest hospital or health centre. (Sources: WHO Cervical Cancer Fact Sheet 2025 ยท PMC meta-analysis 2025 ยท WHO AFRO)
The 5-year survival rate for cervical cancer in sub-Saharan Africa is estimated at approximately 25โ35% across all stages combined โ compared to 67โ72% in the UK and USA and over 75% in Australia. The 2025 PMC meta-analysis (PMC12550229, 57 studies, 2000โ2024) found a pooled mortality incidence (death within the study follow-up period) of 32.06% across SSA studies. Stage at diagnosis is the overwhelming determinant of survival: Stage I cervical cancer has 5-year survival of approximately 80โ90% โ even in African settings with limited radiotherapy. Stage IV cervical cancer has 5-year survival of less than 10โ15%. This dramatic stage-dependent difference explains why the absence of screening is so deadly โ screening catches cervical cancers (or pre-cancers) at Stage 0 or I when surgery or simple treatment can cure. By the time symptoms appear and women present, Stage IIIโIV dominates (estimated 70โ80%+ of presentations in SSA), and the survival outlook is poor. Nigeria's ~22 per 100,000 mortality rate vs Australia's 1.44 per 100,000 is almost entirely explained by this difference in stage at presentation, not by different disease biology or treatment quality per stage. (Sources: PMC meta-analysis PMC12550229 ยท 2025 ยท WHO ยท GLOBOCAN 2022)
๐ How to Cite This Page
Copy your preferred citation format below. For permission to reproduce charts, contact [email protected]
APA (7th Edition)
Enavec Pharmacy Data Team. (2025, April). How many women die from cervical cancer in Africa? [2024 statistics, data & trends]. Enavec Pharmacy. https://enavecpharmacy.com/how-many-women-die-from-cervical-cancer-in-africa-2024-statistics-data-trends/
MLA (9th Edition)
Enavec Pharmacy Data Team. "How Many Women Die from Cervical Cancer in Africa? [2024 Statistics, Data & Trends]." Enavec Pharmacy, Apr. 2025, enavecpharmacy.com/how-many-women-die-from-cervical-cancer-in-africa-2024-statistics-data-trends/.
Plain Text
Enavec Pharmacy (April 2025). How Many Women Die from Cervical Cancer in Africa? Data sourced from: GLOBOCAN 2022 (IARC/WHO, April 2024); WHO Regional Office for Africa (2023); PMC11411759 (2024); PMC12276544 (2025); PMC meta-analysis PMC12550229 (2025). URL: https://enavecpharmacy.com/how-many-women-die-from-cervical-cancer-in-africa-2024-statistics-data-trends/
Primary data sources: GLOBOCAN 2022 (Bray et al., CA Cancer J Clin, April 2024) ยท WHO Regional Office for Africa 2023 ยท PMC11411759 (2024) ยท PMC12276544 (2025) ยท PMC12550229 (2025). For permission to reproduce charts, contact [email protected]
๐ Primary References & Data Sources
1
Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229โ263. doi:10.3322/caac.21834. PubMed 38572751.
2
WHO Regional Office for Africa (AFRO). Off-track cervical cancer progress risks 70,000 deaths every year in Africa. Official WHO AFRO statement. August 31, 2023. afro.who.int/news/track-cervical-cancer-progress-risks-70-000-deaths-every-year-africa
3
WHO Regional Office for Africa (AFRO). Cervical cancer health topic page. In 2022, the region accounted for 23% of global cervical cancer mortality. afro.who.int/health-topics/cervical-cancer
4
PMC11411759 (2024). Accelerating HPV vaccination in Africa for health equity. National Center for Biotechnology Information. PubMed Central. "117,316 women in Africa are diagnosed, of which 76,745 die from the disease every year."
5
PMC12276544 (2025). Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022. Eastern Africa ASMR: 28.87 per 100,000. Eswatini: 64.3 per 100,000. ScienceDirect / PMC.
6
PMC12550229 (2025). Incidence and predictors of mortality among cervical cancer patients in Sub-Saharan Africa: a systematic review and meta-analysis. Pooled mortality: 32.06%. 57 studies. American Journal of Obstetrics and Gynecology.
7
WHO Cervical Cancer Fact Sheet. Cervical cancer: key facts. "Women living with HIV are 6 times more likely to develop cervical cancer." December 2, 2025. who.int/news-room/fact-sheets/detail/cervical-cancer
8
Jedy-Agba E, Joko WY, Liu B et al. Trends in cervical cancer incidence in sub-Saharan Africa. British Journal of Cancer. 2020;123:148โ154. doi:10.1038/s41416-020-0831-9. PMC7341858. (10 registries, 8 countries, 21,990 cases)
9
Yang L, Boily MC, Rรถnn M et al. Regional and country-level trends in cervical cancer screening coverage in sub-Saharan Africa. PLoS Medicine. 2023. doi:10.1371/journal.pmed.1004143. PMC9882915.
10
ScienceDirect / Journal of Cancer Policy (2022). Trends in cervical cancer screening research in sub-Saharan Africa: a bibliometric analysis 2001โ2020. "each year approximately 80,000 women are diagnosed with cervical cancer, and just over 60,000 die from the disease in this region." doi:10.1016/j.jcpo.2022.100359
11
Lancet Oncology Commission on Cancer in Sub-Saharan Africa. Cancer in sub-Saharan Africa. Lancet Oncology. 2022;23(6):e251โe312. doi:10.1016/S1470-2045(21)00720-8. PMC9393090.
12
PubMed (GLOBOCAN 2022 projections). Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030. Published July 2025. doi:10.1093/jnci/djaf035. "760,082 new cases (14.8% increase) and 411,035 deaths (17.8% increase) by 2030."
13
ScienceDirect (2025). Global, regional, and national burden of cervical cancer in 2022 and projections to 2050: a population-based analysis. doi:10.1016/j.ygyno.2025.05.002. GLOBOCAN 2022 global ASMR: 7.08 per 100,000.
Get Screened, Get Vaccinated โ Protect Yourself From Cervical Cancer
Cervical cancer is almost entirely preventable. If you are a woman between 25 and 65, ask our pharmacists about HPV vaccination options and where to access cervical cancer screening near you. Early detection saves lives โ and in Africa, most deaths occur simply because screening was never done.
โ๏ธ This page is for educational and data journalism purposes only. All statistics are sourced and cited. For medical advice, consult a qualified healthcare professional. No product prices are quoted in this article.
Found this helpful? Share it:
⚠️
Medical & Affiliate Disclaimer This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement or medication. Some links in this post are affiliate links - if you purchase through them, Enavec Pharmacy may earn a small commission at no extra cost to you.
